TrialThe Lancet. Haematology2016

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

Ryotaro Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.